ArticleLancet regional health. Americas2026
Economic and health burden of severe respiratory syncytial virus infection among hospitalised children at three tertiary hospitals in Argentina, Brazil, and Colombia: a two-year prospective multicentre cohort study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection (LRTI) in young children, yet prospective data on its societal and health burden in Latin America remain scarce. We estimated the direct medical, direct non-medical, and indirect costs and the health burden (disability-adjusted life years, DALYs) of severe RSV-associated LRTI, compared with RSV-negative children hospitalised with severe LRTI, in three Latin American countries. Methods: We conducted a prospective multicentre cohort study between May 2023 and May 2025 among children aged 1-59 months hospitalised with severe LRTI in three tertiary hospitals in Argentina, Brazil, and Colombia. RSV was confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR). Individual-level data on healthcare utilisation, household out-of-pocket expenditures, and caregiver productivity losses were collected. Costs were estimated by bottom-up micro-costing and expressed in June 2025 purchasing power parity-adjusted US dollars (USD PPP). DALYs per episode were summarised by country, RSV status, and level of care. Findings: Among 747 children, 368 (49%) were RSV-positive. Intensive care unit (ICU) admission was the main driver of both costs and DALYs: mean total societal costs per episode were two-to six fold higher for ICU than forward admissions (in Argentina, USD PPP 22,099 vs 3479 among RSV-positive children), and median DALYs were three-to five fold higher (0.0058 vs 0.0011). Costs varied widely across sites but differed minimally by RSV status; differences between RSV-positive and RSV-negative episodes were small and non-significant in all three sites (all 95% confidence intervals [CIs] included zero). Interpretation: Severe RSV disease imposes a substantial economic and health burden across the three tertiary hospitals studied in Argentina, Brazil, and Colombia. ICU admission, rather than RSV status, is the main determinant of per-episode costs and DALYs, providing evidence to inform policy on RSV prevention. Funding: Merck Investigator Studies Program (MISP).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.